Growth was led by our EMG product line, where sales of our recently launched next-generation UltraPro S100 neuromuscular diagnostic device contributed to a 26% year-over-year increase for EMG. And as another point of reference, our Q1 Neuro revenue was 11% higher than the first quarter of 2019. Overall, our Neuro business increased by 6% year-over-year during the first quarter, with growth and recovery in all major product areas.
Natus ultrapro s100 full#
We have the most comprehensive line of neurodiagnostic equipment offered by any global manufacturer today, offering a full line of EEG, EMG and PSG solutions. Our products and services are used by the majority of hospitals and neurologists worldwide. Natus is a global leader in neurodiagnostic equipment solutions. In a few minutes, Drew will discuss more financial details, but first, I'd like to provide some additional commentary on the quarter in each of our end markets. We see strong customer interest in our newly released Retcam Envision, ALGO 7i newborn hearing screener and our Otoscan digital ear screener - ear scanner, which continues to build momentum in the market. We continue to believe our efforts to reduce our cost structure and investment in new products will drive long-term revenue growth and profitability. We are optimistic in the pace of our revenue recovery in 2021 compared to 2020. Our non-GAAP earnings per share grew 317% compared to the first quarter of 2020 on very similar revenues as a result of the operating expense improvements that we have delivered over the last two years. Our Neuro, Newborn Care and Hearing & Balance end markets all experienced growth compared to the first quarter of 2020. Our revenues in the first quarter of 2021 grew 5% compared to the first quarter of 2020, which was impacted by the pandemic late in that quarter.
Revenue was higher than expected, while our earnings per share was in line with our expectations. Revenue for the quarter was $114.9 million and non-GAAP earnings per share was $0.16. Today, we reported the results for the first quarter of 2021. During our call today, we will discuss our first quarter 2021 financial results as well as our current business trends. Kennedy - President, Chief Executive Officer and Director I would now like to turn the call over to Jonathan Kennedy, President and Chief Executive Officer of Natus Medical. You can find a reconciliation of our financial results on a GAAP versus non-GAAP basis in today's earnings release. Management believes that the presentation of these non-GAAP measures, along with our GAAP financial statements, provide a more thorough analysis of our ongoing financial performance. The non-GAAP results exclude amortization expenses, reconstructing and certain other charges and their related tax effects. Management's presentation of the financial results will be on a GAAP and non-GAAP basis. Our actual results may differ materially from these forward-looking statements.Ī description of relevant risks and uncertainties pertaining to our business, please see today's press release and our periodic annual reports filed with the SEC. These statements include management's beliefs and expectations about our future results. Today's call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Finally, Drew will return the call to Jonathan for closing remarks. Jonathan will begin today with a business overview of the first quarter in 2021, then Drew will discuss the first quarter financial performance. On the call today from Natus is Jonathan Kennedy, Natus' President and Chief Executive Officer and Drew Davies, Natus' Executive Vice President and Chief Financial Officer. Good afternoon, everyone, and thank you for joining us today to review our results for the first quarter of 2021. Natus Medical Incorporated ( NTUS) Q1 2021 Earnings Call May 6, 2021, 4:30 p.m.
0 kommentar(er)
